Sep 23 2014
Enable Injections, developer of a novel wearable 'bolus injector' that may soon make it easy and nearly painless for patients to self-inject large-dose biologic drugs in the comfort of their homes, has been named winner of the 'Buzz of BIO Investor Forum' contest recognizing highly innovative companies in the biotech sector.
Enable is one of only two 'Buzz of BIO' winners, and received the greatest number of votes in the "Late Stage Leaders" category.
Bolus injectors are a new drug delivery device class for subcutaneous self-administration of biologics. Enable Injections' bolus injector is a subcutaneous alternative to IV delivery that allows patient self-injections of high volume or viscous biological drugs.
"Winning the Buzz of Bio contest and being recognized as a leading biotech innovator is an honor. There is growing awareness of the urgent need for body-worn injectors that can deliver the many promising large-volume biologics in development, and our bolus injector is receiving very positive reviews," says Michael Hooven, CEO of Enable Injections. "We are grateful for the BIO community's recognition and look forward to presenting at the BIO Investor Forum."
The novel wearable injector developed by Enable Injections, only slightly larger than an Oreo cookie, adjusts the delivery rate of the drug based on the patient's tissue pressure to create a personalized, more comfortable injection experience. It is also the only injectable device to incorporate a pause feature, giving the patient more flexibility and control.
SOURCE Enable Injections, LLC
Do GLP-1 drugs cause cancer? New review says no, may even protect